Urszula Wojtyra

Update On Biosimilars In Canada – June 2025

Health Canada Consultation On Revised Biosimilar Guidance: No Requirement For Comparative Clinical Efficacy And Safety Trials

2024 Highlights In Canadian Life Sciences IP And Regulatory Law

Agile Licensing Amendments Registered

PMPRB Releases New Draft Guidelines For Comment

PM(NOC) Regulations: Seven-year Anniversary Of Major Amendments

Manitoba Last Province To Introduce Biosimilars Initiative, While Ontario Adds Four Drugs To Its Biosimilar Policy

2024 Mid-Year Highlights In Canadian Life Sciences IP And Regulatory Law

Update On Biosimilars In Canada – March 2024

Federal Court Finds PMPRB Reasonably Concluded Galderma's Patent Claiming 0.3% Adapalene "Pertained To" 0.1% Adapalene DIFFERIN